Publications
Detailed Information
Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice
Cited 0 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Issue Date
- 2007
- Citation
- J Vet Sci 2007, 8, 383-392
- Abstract
- We previously induced protective immune response by
oral immunization with yeast expressing the ApxIIA
antigen. The ApxI antigen is also an important factor in
the protection against Actinobacillus pleuropneumoniae serotype
5 infection; therefore, the protective immunity in
mice following oral immunization with Saccharomyces cerevisiae
expressing either ApxIA (group C) or ApxIIA
(group D) alone or both (group E) was compared with that
in two control groups (group A and B). The immunogenicity
of the rApxIA antigen derived from the yeast was
confirmed by a high survival rate and an ApxIA-specific
IgG antibody response (p < 0.01). The highest systemic
(IgG) and local (IgA) humoral immune responses to
ApxIA and ApxIIA were detected in group E after the
third immunization (p < 0.05). The levels of IL-1β and
IL-6 after challenge with an A. pleuropneumoniae field isolate
did not change significantly in the vaccinated groups.
The level of TNF-α increased in a time-dependent manner
in group E but was not significantly different after the
challenge. After the challenge, the mice in group E had a
significantly lower infectious burden and a higher level of
protection than the mice in the other groups (p < 0.05).
The survival rate in each group was closely correlated to
the immune response and histopathological observations
in the lung following the challenge. These results suggested
that immunity to the ApxIA antigen is required for optimal
protection.
- ISSN
- 1229-845X
- Language
- English
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.